---
title: "BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295701512.md"
description: "Phase 2 SUNRISE-PD trial in early Parkinson's showed bezisterim provided statistically significant benefits over placebo across motor and non-motor symptoms, with the largest effects in patients with higher baseline inflammation. Bezisterim demonstrated favorable biomarker shifts, reduced neurodegeneration markers, and was well-tolerated, supporting advancement to Phase 3.Original document: BioVie Inc. [BIVI] Slides Release — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T19:45:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295701512.md)
  - [en](https://longbridge.com/en/news/295701512.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295701512.md)
generator: "portal-rs"
---

# BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3

Phase 2 SUNRISE-PD trial in early Parkinson's showed bezisterim provided statistically significant benefits over placebo across motor and non-motor symptoms, with the largest effects in patients with higher baseline inflammation. Bezisterim demonstrated favorable biomarker shifts, reduced neurodegeneration markers, and was well-tolerated, supporting advancement to Phase 3.

Original document: BioVie Inc. \[BIVI\] Slides Release — Aug. 12 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md)
- [BIVIW.US](https://longbridge.com/en/quote/BIVIW.US.md)

## Related News & Research

- [BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration](https://longbridge.com/en/news/295718009.md)
- [BioVie says Phase 2 SUNRISE-PD trial shows bezisterim improves motor and non-motor symptoms in early Parkinson’s disease](https://longbridge.com/en/news/295101020.md)
- [Rhelion signs supply license with Toronto’s UHN for psilocybin trial in Parkinson’s depression](https://longbridge.com/en/news/296134949.md)
- [Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses](https://longbridge.com/en/news/296405637.md)
- [BioVie posts corporate presentation outlining bezisterim, BIV201 clinical programs in neurodegeneration, Long COVID, liver disease](https://longbridge.com/en/news/295220567.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**